BIO 103 - Biophytis
Latest Information Update: 01 Jul 2016
At a glance
- Originator Biophytis
- Mechanism of Action Proto-oncogene protein c-mas-1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Muscular atrophy
Most Recent Events
- 01 Jul 2016 Preclinical trials in Muscular atrophy in France (PO)